Dec 21 (Reuters) - Celgene Corp said its cancer drug in a combination therapy did not prove to be better than another treatment that included standard of care and chemotherapy in newly diagnosed immune system cancer patients in a late-stage study.
The company’s shares fell 5.8 percent to $102.10 in extended trading on Thursday.
The study, which tested the company’s blockbuster drug, Revlimid, along with rituximab, failed to show that the chemotherapy-free regimen prevented the disease from progressing, compared to the control arm.
The late-stage trial also did not show an increase in the number of patients who fully responded to the company’s combination treatment, Celgene said. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)